The European Union has secured up to 405 million doses of the CureVac vaccine should it receive regulatory approval. Despite being a laggard in the vaccine race, CureVac believes it has advantages over mRNA competitors. CureVac’s product can be stored at standard refrigerator temperature, unlike the first-generation Pfizer and Moderna vaccines which require super-cold freezers. The company is already working on a second-generation Covid vaccine for which it has teamed up with pharma giant GSK. The move came shortly after media reports said then President Donald Trump had sought exclusive US access to any CureVac vaccine, a claim both sides strenuously denied.

Source: The Local June 30, 2021 23:15 UTC